Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Caitlin E. Cox

December 05, 2017

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

News Conference News AHA 2017

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Michael O'Riordan

November 16, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Diabetes Remission Possible With Significant Weight Loss: DiRECT

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Genetic Study Hints at Role of Lipids in AAA Risk

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Statins and Diabetes: Causal Link Reinforced in New Analysis

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Merck Calls Quits on CETP Inhibitor Anacetrapib

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content